Industry: Psychedelics
Funding for psychedelic startups
Investors in psychedelic medicine now pay for late-stage data, FDA filings and the clinics that will give each dose. We build that case for drug developers and therapy clinics.
- Investor materials for drug developers and therapy clinics
- Models built on trial costs, rescheduling and clinic capacity
- Waveup prepares investor materials for psychedelic medicine companies: $3B+ raised for 600+ startups since 2014
In short
What is funding for psychedelic startups?
Funding for psychedelic startups is the money raised by psilocybin, LSD and MDMA drug developers and by psychedelic therapy clinics. It comes from neuroscience funds, life sciences investors, public markets and drugmakers that license or buy drugs. In Q2 2026 the field raised just over $1B, a record, but one company took most of it.
- Who it's for
- Psychedelic drug developers and therapy clinics, pre-seed to Series D+
- What we build
- Investor deck, financial model, valuation, investor list, data room
- Prices
- Deck from $6,000, model from $3,000. Flat fees
- Track record
- $3B+ raised for 600+ startups since 2014
Market data checked on 6 November 2026. Sources are under each section.
Are investors back in psychedelic medicine in 2026?
Yes, for drug developers with late-stage data. Early-stage companies and clinics still find money scarce.
The opportunity
The first psychedelic drugs are nearing FDA decisions, and big drugmakers have started buying.
- Compass Pathways expects to finish its psilocybin drug application in November 2026
- AbbVie and Otsuka have each bought a drug programme in the field
- An April 2026 executive order backs faster FDA reviews for breakthrough-designated psychedelics
The problem
Most of the money goes to a few listed drug developers with Phase 3 data. In Q2 2026, Definium alone raised $805M, while very few private companies raised at all.
Market size
How big is the market for psychedelic medicine, and what will drive it?
No psilocybin, LSD or MDMA medicine is approved in the US yet, so there are no sales to count. The nearest guide is J&J's Spravato, a ketamine-based nasal spray taken in certified clinics. It sold $1.7 billion worldwide in 2025. Four things will shape demand for the first approved psychedelic drugs:
- Late-stage data: Definium's LSD drug, DT120, reported positive results in three Phase 3 trials in 2026
- Faster reviews: a national priority voucher could cut Compass's FDA review to 1–2 months
- Federal money: a 2026 executive order directs at least $50M to state psychedelic programmes
- Supervised services: Oregon's licensed psilocybin service centers served 5,935 clients in 2025
Venture capital
How much money reaches psychedelic companies now?
Psychedelic financing rises and falls with trial results. Q2 2026 set a record after Definium's Phase 3 data, but few private companies raised that quarter.
financings in Q2 2026, which brought in just over $1B, a quarterly record
Series A total for Reunion Neuroscience after its 2025 extension
Series A for Gilgamesh Pharma in early 2026, after AbbVie bought its parent's lead drug
Who invests in psychedelic startups?
Neuroscience and psychedelics funds, a life sciences VC and drugmakers that buy programmes. For more names, see our list of psychedelic venture capital firms.
Investor database
Pharma investors in our database
The funds with the most pharma investments. Pick a stage, or open a fund for its cheque sizes.
Top 5 by pharma investments
Investments by industry
- Healthtech & Wellness42%
- Pharma19%
- Biotech17%
- Rounds
- Pre-seedSeed
- Average cheque
- Not listed
- Based in
- Los Angeles, California, United States
28 investments in total, 7 tagged Pharma.Open the full fund profile
Investments by industry
- Healthtech & Wellness40%
- Software & Apps15%
- Pharma7%
- Rounds
- Pre-seedSeedSeries ASeries BSeries C+
- Average cheque
- Not listed
- Based in
- Dallas, United States
- Invests in
- USA
88 investments in total, 7 tagged Pharma.Open the full fund profile
Investments by industry
- Healthtech & Wellness49%
- Biotech20%
- Pharma14%
- Rounds
- SeedSeries A
- Average cheque
- Not listed
- Based in
- Toronto, Ontario, Canada
25 investments in total, 5 tagged Pharma.Open the full fund profile
Investments by industry
- Biotech21%
- Healthtech & Wellness19%
- Hardware. Robotics & IoT17%
- Pharma7%
- Rounds
- SeedSeries ASeries BSeries C+
- Average cheque
- $1M–$3M$3M–$10M
- Based in
- Jackson, United States
- Invests in
- USA
62 investments in total, 3 tagged Pharma.Open the full fund profile
Investments by industry
- Healthtech & Wellness50%
- Biotech19%
- Pharma6%
- Rounds
- Seed
- Average cheque
- Not listed
- Based in
- San Francisco, United States
- Invests in
- Europe, USA, Canada
33 investments in total, 2 tagged Pharma.Open the full fund profile
From our investor database.
Why do investors hesitate on psychedelic companies?
In our Fundraising 2025 study, 56 VCs named burn and missed milestones among their top reasons to say no. Psychedelic developers face long trials and a second approval step, so both risks weigh heavily.
Costly dosing sessions
FDA guidance from July 2026 expects two trained monitors in the room for each full dosing session. Every trial visit carries those staff hours.
What investors ask
- What does one dosing session cost, and how many does your trial need?
What your deck shows
- Cost per session, with staff hours
- Trial budget and cash to each readout
Approval isn't launch
Many psychedelics are Schedule I drugs, so an approved product also needs DEA and state rescheduling. Compass says about 90% of US patients live in states that intend to reschedule within weeks.
What investors ask
- How long from FDA approval to first sale, state by state?
What your deck shows
- A timeline from filing to DEA and state rescheduling
- A launch plan that starts where rules allow
Clinic hours cap sales
Spravato patients must stay in a certified clinic for at least two hours after each dose. The FDA notes that patients may stay vulnerable for several hours or longer after a psychedelic dose.
What investors ask
- How many sessions can one room run a day, and who pays for that time?
What your deck shows
- Revenue and staff cost per session and per room
- A payer plan, or a cash price clinics will accept
A gap after early data
Psychedelic Alpha found no announced private Series B or C rounds from 2023 until mid-2025. Even in Q2 2026's record quarter, very few private companies raised.
What investors ask
- How will you fund the step from early data to Phase 3?
What your deck shows
- The milestone each tranche of money reaches
- Licensing, partnering or grant options beside equity
How we help you raise
Flat fees agreed before we start. No success fee on advisory work.
Trial data, the FDA and DEA path and your clinic model in one story.
Trial costs, session staffing, launch timing and runway, month by month.
A range built on recent psychedelic deals and the risk left before approval.
Neuroscience funds, life sciences VCs, drugmakers and grant bodies for your stage.
Trial records, DEA registrations, patents and contracts, ready for review.
For a licensing deal, an asset sale or a buyer's diligence.
Who we are
Waveup is a London-based fundraising and growth advisory, working in 60+ countries and 90+ industries. Since 2014 we have built the decks, models, CIMs and valuations behind $3B+ raised for 600+ startups. Biotech and pharma are the largest group among our 54+ deep-tech projects.
About usFunding for psychedelic startups FAQ
How do psychedelic startups get funding?
Which companies are developing psychedelic medicines?
Are psychedelics becoming legal in the US?
What do investors look for in a psychedelic drug developer?
Can a psychedelic therapy clinic raise venture capital?
How much does help with a psychedelic company's raise cost?
Raising for a psychedelic medicine company?
Tell us your drug or clinic model and the round you plan. We'll flag what investors will question first.



